Brief: Matinas Biopharma Provides Business Update And 2022 Strategic Outlook
25/01/2022 13:03
Jan 25 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA PROVIDES BUSINESS UPDATE AND 2022
STRATEGIC
OUTLOOK
* MATINAS BIOPHARMA - COHORT 4 OF ENACT (ALL ORAL INDUCTION
REGIMEN) UNDERWAY WITH SIX PATIENTS ENROLLED AND TOPLINE INTERIM
DATA EXPECTED Q3 2022
* MATINAS BIOPHARMA - ENDED 2021 WITH $49.9 MILLION,
SUFFICIENT TO
FUND PLANNED OPERATIONS THROUGH 2023
Source text for Eikon: ID:nGNX4bJskC
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors